Psilocybin Therapy For Autism-Like Disorder Receives Approval For Phase 2a Clinical Trial Dec 28, 2022
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360… Nov 9, 2021
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder Nov 3, 2021
COMPASS Pathways Teams with UK Institutions to Research Innovations in Mental Health Care Jul 7, 2021
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb… Jun 28, 2021
